Archive
542 articles, sorted by publication time.
The FDA approval of Orca Bio's donor cell therapy TREGZI is not about pushing the immune system harder, but about trying to restore order after hematopoietic stem cell transplantation; this shifts prevention of chronic graft-versus-host disease from drug-based suppression toward precise regulation of cellular composition.
The decision extends the role of immune cell therapy from attacking cancer cells to regulating runaway immune responses after transplantation; but with limited public data, its clinical value still needs to be weighed in the context of patient characteristics, treatment accessibility, and long-term safety.
The partnership between Mankind Pharma and Denovo Sciences shows that AI drug discovery is moving from demonstrating model capabilities toward the more difficult work of experimental screening and R&D judgment.
BK virus infection after kidney transplantation has long lacked dedicated drugs, with treatment often caught between antiviral control and preserving the graft; Ipsen’s acquisition of Memo Therapeutics pushes this clinical gap into late-stage development.
The FDA has approved the first blood cancer transplant therapy centered on regulatory T cells, pushing allogeneic hematopoietic stem cell transplantation beyond engraftment and anticancer effects to include long-term immune imbalance in treatment design.
Claude Science brings large language models more formally into the drug development workflow; it is not an automatic drug-making machine, but a commercial test of research efficiency, evidence verification, and the boundaries of biosafety.
This cell therapy does not simply transfer hematopoietic stem cells into the patient’s body. Instead, it attempts to recalibrate the composition of donor immune cells to reduce the risk of chronic rejection, one of the most difficult challenges after allogeneic transplantation.
This new therapy centered on donor regulatory T cells gives blood cancer transplant treatment another path for reducing chronic immune damage; however, public information remains limited, and the boundaries of efficacy and real-world accessibility still require fuller data.
From protein folding to joint modeling of drug molecules, nucleic acids, and antibody interfaces, AlphaFold 3 pushes structural biology questions closer to laboratory decision-making; but what it provides is a better molecular map, not yet an answer to whether a drug will succeed or fail.
Elevidys received traditional approval for ambulatory patients while also including non-ambulatory patients under accelerated approval; this is not a simple declaration of victory, but a case study in how rare disease gene therapies balance limited evidence, urgent need, and long-term validation.
The partnership between a major Indian pharmaceutical company and an AI drug R&D company reflects how the pharmaceutical industry is bringing algorithms into early-stage R&D workflows; but before data, experimental validation, and clinical translatability are publicly disclosed, this remains a technology bet that needs evidence to support it.
This is not a clinical data release, but a moment in which a small biotech company is trying to reshape its R&D narrative through a transaction; the real test will begin only after the candidate therapies, validation data, and integration capabilities are gradually laid out.